STATE HIGHLIGHTS DAIICHI SANKYO DURING LIFE SCIENCES WEEK
Trenton, N.J. (November 29, 2007) – Governor Corzine’s Economic Growth Strategy has placed high priority on encouraging innovation and maintaining the state’s position as a leader in technology and life sciences. To support this important industry sector, he proclaimed the week of November 26 to December 3 as “Life Sciences Week.”
To emphasize the valuable contribution that pharmaceutical, biotechnology and life science companies have made to the state, the Governor highlighted Daiichi Sankyo, Inc., a global pharmaceutical company with its U.S. headquarters in Parsippany, New Jersey, during Life Sciences Week.
“Daiichi Sankyo is a shining example of a growing pharmaceutical company,” Governor Jon S. Corzine said. “We appreciate that the company has made an investment in New Jersey and we will continue to work closely with them to encourage and support this rapid growth. I am particularly pleased to mark the success of this company during Life Sciences Week.”
Daiichi Sankyo, an emerging leader in cardiovascular care, has been experiencing stable and sustained growth in a pharmaceutical market that has seen many larger companies forced to downsize and consolidate operations.
During the past five years, the company’s U.S. Headquarters staff and its Edison-based global Clinical Development staff have both more than doubled in size. The company’s most recent expansion plans include growth of the Parsippany headquarters office to 185,000 square feet in 2008. Further, the addition of a new Parsippany Training Center early next year will add another 32,000 square feet and provide space to train its growing U.S. sales force. The company expects to achieve a 60 percent growth in sales over the next three years.
Since 2004, New Jersey has assisted Daiichi Sankyo in their expansion planning and approved a Business Employment Incentive Program (BEIP) grant in 2006 through New Jersey’s Economic Development Authority (NJEDA).
“We are continuing Daiichi Sankyo’s tradition of solid R&D innovation and drug discovery, and our company is well positioned to excel in the challenging U.S. marketplace. We are committed to bringing more life science jobs to New Jersey,” said President and CEO Joseph P. Pieroni. “The State of New Jersey has created a business environment to help cultivate the life sciences industry, and Daiichi Sankyo is thankful for the opportunity to utilize those incentives to assist with our growth.”
The Governor’s Economic Growth Strategy has placed high priority on encouraging innovation and maintaining the state’s position as a leader in technology and life sciences, including workforce training initiatives to help workers develop advanced skills in order to qualify for high-quality jobs in this growing industry sector. Launched alongside the Governor’s Economic Growth Strategy, the Edison Innovation Fund was developed to create, sustain, and grow high-tech businesses in the state. The fund increases access to early stage capital and provides specialized assistance to existing mid-sized and large technology and life sciences businesses.
Governor Corzine’s initiatives to establish public-private partnerships with the life sciences industry have been recognized over the past two years with $15 million in federal Workforce Innovation in Regional Economic Development (WIRED) grants.
Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., Japan’s second largest pharmaceutical company and a global leader in pharmaceutical innovation since 1899, including the discovery of the statin class of lipid-lowering agents.
Globally, Daiichi Sankyo currently ranks as one of the top twenty pharmaceutical companies with sales last year exceeding $8 billion. The company develops and markets drugs in five therapeutic areas: cardiovascular, metabolic disease, oncology, immunology and anti-infectives.
For more information, call Pamela McClure at 609.292.2523 or e-mail email@example.com.